突发！辉瑞21亿美元买走中国减肥药

药闻社2025-12-14

点击上面“蓝字”关注我们！本文来源于招财部落；如果喜欢，欢迎在文末处点个“在看”，感谢您的支持！最近减肥药赛道可真热闹，上个月辉瑞刚砸下100亿美元收购Metsera，如今又巨资锁定中国小分子减肥药。就在今晚，复星医药发布公告控股子公司药友制药、复星医药产业与辉瑞共同签订《许可协议》，将药友制药旗下口服小分子胰高血糖素样肽-1受体（GLP-1R）激动剂研药物YP05002及其相关产品的全球独家开发...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2591667541?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-14 23:22","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2591667541","market":"us","top_or_hot":-1,"title":"突发！辉瑞21亿美元买走中国减肥药","media":"药闻社","content":"<div>\n<p>点击上面“蓝字”关注我们！本文来源于招财部落；如果喜欢，欢迎在文末处点个“在看”，感谢您的支持！最近减肥药赛道可真热闹，上个月辉瑞刚砸下100亿美元收购Metsera，如今又巨资锁定中国小分子减肥药。就在今晚，复星医药发布公告控股子公司药友制药、复星医药产业与辉瑞共同签订《许可协议》，将药友制药旗下口服小分子胰高血糖素样肽-1受体（GLP-1R）激动剂研药物YP05002及其相关产品的全球独家开发...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214232543a6a193f2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>突发！辉瑞21亿美元买走中国减肥药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n突发！辉瑞21亿美元买走中国减肥药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-14 23:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214232543a6a193f2&s=b><strong>药闻社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>点击上面“蓝字”关注我们！本文来源于招财部落；如果喜欢，欢迎在文末处点个“在看”，感谢您的支持！最近减肥药赛道可真热闹，上个月辉瑞刚砸下100亿美元收购Metsera，如今又巨资锁定中国小分子减肥药。就在今晚，复星医药发布公告控股子公司药友制药、复星医药产业与辉瑞共同签订《许可协议》，将药友制药旗下口服小分子胰高血糖素样肽-1受体（GLP-1R）激动剂研药物YP05002及其相关产品的全球独家开发...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214232543a6a193f2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214232543a6a193f2&s=b","article_id":"2591667541","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214232543a6a193f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2591667541","pubTimestamp":1765725731,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"最近减肥药赛道可真热闹，上个月辉瑞刚砸下100亿美元收购Metsera，如今又巨资锁定中国小分子减肥药。在今年中国创新药飞涨的行情中，辉瑞接洽国内药企洽谈减肥药BD出海的小作文层出不穷。从今年的数据看，礼来的GLP-1双靶点药物替尔泊肽今年前三季度销售额高达186.8亿美元，全年有望突破350亿美元，拿下GLP-1RA减肥药57%的市场份额。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4581":"高盛持仓","LU0058720904.USD":"联博国际健康护理基金A","BK4599":"减肥药","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SG9999001176.USD":"United Global Healthcare Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4534":"瑞士信贷持仓","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4585":"ETF&股票定投概念","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4592":"伊斯兰概念","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4007":"制药","BK4568":"美国抗疫概念","BK4588":"碎股","BK4550":"红杉资本持仓","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","PFE":"辉瑞","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD"},"translate_title":"Suddenly! Pfizer buys Chinese diet pills for US $2.1 billion","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1.5},"content_text":"点击上面“蓝字”关注我们！本文来源于招财部落；如果喜欢，欢迎在文末处点个“在看”，感谢您的支持！最近减肥药赛道可真热闹，上个月辉瑞刚砸下100亿美元收购Metsera，如今又巨资锁定中国小分子减肥药。就在今晚，复星医药发布公告控股子公司药友制药、复星医药产业与辉瑞共同签订《许可协议》，将药友制药旗下口服小分子胰高血糖素样肽-1受体（GLP-1R）激动剂研药物YP05002及其相关产品的全球独家开发、生产及商业化权利授予辉瑞，覆盖人类及动物的所有治疗、诊断及预防适应症。药友制药将获得不可退还的首付款1.5亿美元及基于许可产品临床、商业化进展获得开发里程碑付款至多3.5亿美元，还将获得至多15.85亿美元的销售里程碑款项，以及至多两位数百分比向药友制药支付特许权使用费。YP05002是一款口服小分子胰高血糖素样肽-1受体（GLP-1R)激动剂，GLP-1R火了好几年了，它能够促进胰腺的胰岛素分泌和降低胰高血糖素分泌，并影响中枢抑制食欲减少能量的摄入，用于治疗2型糖尿病、肥胖症及其相关代谢疾病如非酒精性脂肪性肝炎等。这笔交易出乎意外的是，YP05002的研发进展仅仅是于澳大利亚处于I期临床试验阶段。也就是说，仅仅出于早期安全性与药代动力学评估阶段，还没做出人体药效剂量关系数据的情况下就让辉瑞砸下重金，其战略布局的重视程度可见一番。辉瑞的减肥药自研之路可谓坎坷：1）2023年底，首款口服GLP-1候选药物Lotiglipron因临床试验中出现肝酶升高问题被终止；2）2025年4月，GLP-1口服药物Danuglipron也因一名患者在1期试验中出现潜在药物诱导的肝损伤而被叫停；3）2025年8月，因临床数据原因，辉瑞放弃了最后一款GLP-1受体激动剂PF-06954522的开发。三条管线的尝试，三次折戟，辉瑞在GLP-1赛道的自研布局全军覆没。基于对肥胖以及代谢疾病布局的战略考虑，辉瑞不得不转向外部合作与并购。在今年中国创新药飞涨的行情中，辉瑞接洽国内药企洽谈减肥药BD出海的小作文层出不穷。就在11月，辉瑞在诺和诺德截胡风波之后，提高价码最终以100亿美元代价并购了美股创新药企Metsera，获得皮下注射月给药一次的长效胰淀素（Amylin）类似物药物MET-233i等产品，补上了“GLP-1 RA+长效胰淀素（Amylin）”减肥产品缺口。拿下药友制药的GLP-1R激动剂YP05002，又补上了“GLP-1R激动剂+口服小分子”的产品布局。有机构预测，到2030年减肥药市场有望突破千亿美元。从今年的数据看，礼来的GLP-1双靶点药物替尔泊肽今年前三季度销售额高达186.8亿美元，全年有望突破350亿美元，拿下GLP-1RA减肥药57%的市场份额。相比于司美格鲁肽、替尔泊肽等大分子多肽药物，口服小分子药物优势非常明显：生产成本更低、口服吸收更稳定、可能无需与特殊吸收增强剂联用、更方便联合其他药物等，也无需注射笔免受扎针的恐惧。因此，小分子药物在业内公认为是下一代口服GLP-1药物的方向。就在昨天，三家药企的减肥产品公布了新的临床数据引发大涨：1）硕迪生物大涨102%，原因是其口服小分子GLP-1受体激动剂aleniglipron在二期临床数据大获成功，36周减重11.3%且副作用不明显；2）美国创新药企Wave生命科学大涨147%，原因是其siRNA药物在临床一期数据中“减肥增肌”效果明显，且仅需每年注射1-2次；3）歌礼制药大涨大涨18%，愿因在于口服小分子GLP-1药物ASC30美国临床二期表现优异，13周减重7.7%。坐拥千亿美元大空间，资本市场对减肥赛道的每一次优化和进步都给予积极的反馈。回到这次交易的主角重庆药友制药，原本它是重庆地方国企，后来改制，复星医药逐步增持股份至当前的61%。大家对他的印象是一家老牌仿制药企，主要有谷胱甘肽、左氧氟沙星、阿法骨化醇、盐酸依匹斯汀等传统产品。前几年复星集团债务压力大，市场上一度出现要出售药友制药股权的传言。重庆药友制药作为复星医药中最不显山露水的仿制药资产，如今却能斩获国际大药企BD大单的确是个喜出望外的收获。1.5亿美元不可退还的首付款相当于药友一年的净利润，创新转型收获了实实在在的果实。单点突破到逐步赶超是中国创新药崛起的特点，从双抗、ADC再到如今的小分子口服药，中国创新药势不可挡。恭喜持有复星医药的朋友，期待下一个BD大单。end因为公众号平台更改了推送规则，如果不想错过药闻社的文章，记得读完点一下“在看”，这样每次新文章推送才会第一时间出现在你的订阅列表里。原创推荐◆“限抗令”持续升级 川宁生物该如何“讲故事”？（二）◆“限抗令”持续升级 川宁生物该如何“讲故事”？（一）◆六连板亚太药业靠拆迁款续命 CRO前十再无新高峰？◆十年迷茫科伦药业：曾与恒瑞并肩300亿市值 如今相差30倍◆健帆生物的高增长逻辑被破坏了？◆Watson“行医”十年壮志未酬 医疗AI特斯拉呼之欲出◆欧美印齐聚国内万亿市场  中国药企正式面临左右夹击◆255个配方揭开神秘面纱  中成药行业是福是祸？◆围猎赫赛汀！","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591667541","isCrawlerRequest":true}